🇺🇸 FDA
Patent

US 8796270

N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor

granted A61KA61K9/0053A61P

Quick answer

US patent 8796270 (N-[6-(1H-indazol-6-yl)imidazo[1,2-A]pyridin-8-yl]-6-(morpholin-4-yl)pyridazin-3-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor) held by GILEAD CONNECTICUT, INC. expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GILEAD CONNECTICUT, INC.
Grant date
Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K9/0053, A61P, A61P1/00, A61P11/00